Format

Send to

Choose Destination
Am J Kidney Dis. 2020 Jan;75(1):6-8. doi: 10.1053/j.ajkd.2019.07.019. Epub 2019 Oct 28.

Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators.

Author information

1
Dutch Medicines Evaluation Board, Utrecht, the Netherlands.
2
Icelandic Medicines Agency, Reykjavík, Iceland; Landspitali - The National University Hospital of Iceland, Reykjavík, Iceland.
3
Institute of Physiology and Pharmacology, Lithuanian University of Health Sciences, Kaunas, Lithuania; Lithuanian State Medicines Control Agency, Kaunas, Lithuana.
4
German Federal Institute for Drugs and Medical Devices, Bonn, Germany.
5
European Medicines Agency, Amsterdam, the Netherlands.
6
European Medicines Agency, Amsterdam, the Netherlands. Electronic address: thorsten.vetter@ema.europa.eu.
PMID:
31672251
DOI:
10.1053/j.ajkd.2019.07.019

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center